2009 Part D plan instructions
Executive Summary
Final version of CMS "call letter" to potential Part D sponsors outlining requirements for the 2009 benefit year reiterates most of the drug-related policies set out in the draft version released in January (1"The Pink Sheet," Jan. 28, 2008, p. 27). To increase transparency on prior authorization requirements, the final call letter requires that sponsors compile such criteria in a standardized format and post it on plan Web sites. CMS will no longer allow plans to impose prior authorization requirements for Roche's HIV therapy Fuzeon (enfuvirtide), nor will the agency permit gap coverage to be limited to mail order drug purchases. In one change, CMS backs off the proposed requirement for electronic prescription reporting in 2009 and announces it will not make such reporting mandatory until 2010
You may also be interested in...
CMS Seeks Part D Prior Authorization Criteria Transparency In 2009
CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.